Press Releases

Filter Press Releases:



  • Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

    INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology that targets tu…

  • Lilly Declares Fourth-Quarter 2017 Dividend

    INDIANAPOLIS, Oct. 16, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable December 8, 2017, to shareholders of record at the close of business on November 15, 2017. About Eli Lilly and CompanyLilly is a global healthcare leader that un…

  • Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis

    INDIANAPOLIS, Oct. 16, 2017 /PRNewswire/ -- New subgroup analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 REVEL trial of CYRAMZA® (ramucirumab) in advanced non-small cell lung cancer (NSCLC) was presented today at the 18th World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan. Specifically, these new data are…

  • FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer

    INDIANAPOLIS, Oct. 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for its New Drug Application (NDA) for Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 & 6 inhibitor. The NDA was based upon the positive interim results from MONARCH 3, a study of abemaciclib in comb…

  • Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer

    INDIANAPOLIS, Oct. 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 JUNIPER study evaluating Verzenio™ (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS). However, an analysis of the secondary study endp…

  • Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer

    INDIANAPOLIS, Oct. 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating VerzenioTM (abemaciclib), a cyclin-dependent kinase (CDK)4 & 6 inhibitor, in combination with a nonsteroidal aromatase inhibitor (NSAI) (anastrozole or letrozole) were published online in the Journal of Clini…

  • U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent

    INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO) has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection). In the inter partes review (IPR) proceedings initiated by Neptune Generics, LLC and Sandoz In…

  • Additional Delivery of Insulin Ready for Distribution in Puerto Rico

    INDIANAPOLIS, Oct. 5, 2017 /PRNewswire/ -- Today, a new shipment of commercial medicines, including more than 36,000 vials and pens of insulin, arrived in Puerto Rico. The delivery by Eli Lilly and Company (NYSE: LLY) includes 3,000 vials for humanitarian distribution and enough commercial insulin to help re-stock operational pharmacies. Lilly's humanitarian donation now includes 5,400 insulin pe…

  • Lilly Receives U.S. FDA Approval of Verzenio™ (abemaciclib)

  • Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes

    INDIANAPOLIS, Oct. 4, 2017 /PRNewswire/ -- Humalog® Junior KwikPen® [insulin lispro injection 100 units/mL] is now available by prescription for the treatment of diabetes in the U.S. This innovation is the latest in the treatment and delivery options Eli Lilly and Company (NYSE: LLY) offers for people with type 1 or type 2 diabetes. Humalog Junior KwikPen is the only prefilled, disposab…

  • Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement

    INDIANAPOLIS, Oct. 2, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2017 on Tuesday, October 24, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, media an…

  • Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing

    INDIANAPOLIS, Sept. 29, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a number of leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018. Josh Smiley has been promoted to senior vice president and chief financial officer and will become a member of Lilly's executive committee, effective January 1, 2018. Lilly announced…

  • Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

    DANVILLE, Pa., RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 25, 2017 /PRNewswire/ -- In an effort to improve health outcomes of people with type 2 diabetes, Geisinger and Boehringer Ingelheim, on behalf of its diabetes alliance with Eli Lilly and Company (NYSE: LLY), today announced a major collaboration to develop a risk-prediction model for three critical health outcomes commonly associated with t…

  • Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis

    INDIANAPOLIS, Sept. 14, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced new safety and efficacy data from a Phase 2 study of baricitinib in people with moderate-to-severe atopic dermatitis (AD). The results showed that baricitinib in combination with a mid-potency topical corticosteroid (TCS) significantly improved the signs and symptom…

  • Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control

    RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 12, 2017 /PRNewswire/ -- New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) tablets reduced the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, independent of blood sugar control at the start of the study. A reduction in cardiovascular death was also see…

  • Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress

    INDIANAPOLIS, Sept. 11, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that data across its immunology portfolio will be presented at the annual European Academy of Dermatology and Venereology Congress (EADV), including Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation…

  • Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer

    INDIANAPOLIS, Sept. 10, 2017 /PRNewswire/ -- At the European Society for Medical Oncology (ESMO) 2017 Congress today, Phase 3 RANGE data from Eli Lilly and Company (NYSE: LLY) were presented in the Presidential Symposium (abstract#: LBA4_PR). These are the first detailed results from the global, randomized, double-blinded, placebo-controlled RANGE study of CYRAMZA® (ramucirumab), in combinat…

  • Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth

    INDIANAPOLIS, Sept. 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced actions to streamline operations to more efficiently focus resources on developing new medicines and to improve its cost structure. Global workforce reductions, including those from a U.S. voluntary early retirement program, are expected to impact approximately 3,500 positions. With the streamlining…

  • Lilly to Participate in Morgan Stanley Global Healthcare Conference

    INDIANAPOLIS, Aug. 28, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Tuesday, September 12, 2017. Derica Rice, Lilly's executive vice president for global services and chief financial officer, will participate in a fireside chat at 12:55 p.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Present…

  • Boehringer Ingelheim and Lilly to support new American College of Cardiology program to highlight the increasingly important role of cardiologists in reducing cardiovascular risk and cardiovascular death in people with type 2 diabetes

    RIDGEFIELD, Conn. and INDIANAPOLIS, July 31, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the companies will support an American College of Cardiology (ACC) program focused on driving quality improvement in cardiology and addressing the latest research advances in the reduction of cardiovascular risk and cardiovascular mortality in people wi…

  • Lilly Reports Second-Quarter Results

    INDIANAPOLIS, July 25, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2017. $ in millions, except per share data Second Quarter % 2017 2016 Change Revenue $ 5,824.3 $ 5,404.8 8% Net Income - Reported 1,008.0 747.7…

  • Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy

    INDIANAPOLIS and SAN FRANCISCO, July 24, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Nektar Therapeutics (NASDAQ: NKTR) have announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar. NKTR-358, which achieved first human dose in Phase 1 clinical development in March of 2017, has the potential to treat a number of autoimmune and o…

  • Lilly Reaches Settlement Agreement in U.S. Cialis Patent Litigation

    INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has entered into a settlement agreement with generic companies to resolve pending patent litigation in the U.S. District Court for the Eastern District of Virginia regarding the Cialis® (tadalafil) unit dose patent. This patent was previously set to expire on April 26, 2020. As part of the agreement, Cialis exclusi…

  • UK Supreme Court Rules In Lilly's Favor On Alimta Vitamin Regimen Patents

    INDIANAPOLIS, July 7, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the UK Supreme Court has decided in the litigation relating to alternative salt forms of Alimta® (pemetrexed disodium) that Actavis's products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain. The UK Supreme Court also affirmed the indirect infringement findin…

  • Lilly Confirms Date and Conference Call for Second-Quarter 2017 Financial Results Announcement

    INDIANAPOLIS, July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2017 on Tuesday, July 25, 2017. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 9 a.m. Eastern time. Investors, media and…

  • Lilly and Purdue University Announce Strategic Research Collaboration

    INDIANAPOLIS and WEST LAFAYETTE, Ind., July 6, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University today announced a strategic collaboration to conduct life science research. The five-year agreement, where Lilly will provide up to $52 million, marks Purdue's largest strategic collaboration with a single company. "Purdue has enjoyed a long history of engagement with Lil…

  • Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego

    INDIANAPOLIS, June 21, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced completion of a $90 million expansion of its Biotechnology Center in San Diego, California. Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pai…

  • Lilly Declares Third-Quarter 2017 Dividend

    INDIANAPOLIS, June 19, 2017 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2017 of $0.52 per share on outstanding common stock. The dividend is payable September 8, 2017, to shareholders of record at the close of business on August 15, 2017. About Eli Lilly and Company Lilly is a global healthcare leader that uni…

  • Lilly Announces Webcast to Discuss Pain Management Portfolio

    INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, June 19, 2017, to discuss the company's pain management portfolio, including data from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, and data from one Phase 3 study of lasmiditan, an investigational treatment for…

  • Lilly to Participate in Goldman Sachs Global Healthcare Conference

    INDIANAPOLIS, May 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Wednesday, June 14, 2017. Sue Mahony, Ph.D., senior vice president and president of Lilly Oncology and Levi Garraway, M.D., Ph.D., senior vice president of global development and medical affairs for Lilly Oncology will participate in a fires…

  • Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom

    RIDGEFIELD, Conn. and INDIANAPOLIS, May 16, 2017 /PRNewswire/ -- Award-winning actress Angela Bassett, along with 11 leading patient and professional organizations, is joining For Your SweetHeart™: Where diabetes and heart disease meet — a nationwide movement to raise awareness of the critical link between type 2 diabetes and heart disease, the number one killer of people with type 2…

  • Lilly to Participate in Bernstein Strategic Decisions Conference

    INDIANAPOLIS, May 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the Bernstein Strategic Decisions Conference on Wednesday, May 31, 2017. David A. Ricks, Lilly's president and chief executive officer, will participate in a fireside chat at 10 a.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website…

  • Lilly to Participate in UBS Global Healthcare Conference

    INDIANAPOLIS, May 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 23, 2017. Derica Rice, Lilly's executive vice president for global services and chief financial officer, will participate in a fireside chat at 11 a.m., Eastern Time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lil…

  • Eli Lilly and Company Sponsors Arthritis Foundation 'Living Your Yes With RA,' an Initiative to Provide Resources for the Rheumatoid Arthritis Community

    INDIANAPOLIS, Oct. 12, 2016 /PRNewswire/ -- Supported by Eli Lilly and Company (NYSE: LLY), the Arthritis Foundation is launching 'Living Your Yes With RA,' a new initiative designed to empower people living with rheumatoid arthritis (RA) by giving them tools, education and resources, allowing them to expect more from their RA treatment - seeking remission or low disease activity as the only acce…

  • Lilly's First Volunteer Teams of 2016 Depart in May for Thailand and Ghana

    INDIANAPOLIS, May 19, 2016 /PRNewswire/ -- A team of Eli Lilly and Company (NYSE: LLY) volunteers from its operations worldwide is on the ground in Thailand, working with a local hospital and health volunteers as part of Lilly's Connecting Hearts Abroad global employee volunteer program. A second team of volunteers will depart next week to serve in Ghana. Nine more teams of Lilly volunteers will…

  • Lilly and United Way Celebrate Deepening Partnership, Community Impact

    INDIANAPOLIS, Nov. 5, 2015 /PRNewswire/ -- Representatives from Eli Lilly and Company (NYSE: LLY) and United Way and its partner agencies gathered today to celebrate the early success of a new partnership approach that includes pairing Lilly teams with United Way agencies and a record gift of $13 million. The results will be shared today from 4-6 p.m. at an Impact Celebration event hosted at the…

  • Diabetes Scholars Foundation Announces 2015 Scholarship Recipients

    ROLLING MEADOWS, Ill. and INDIANAPOLIS, June 25, 2015 /PRNewswire/ -- Attending college is a critical milestone in the lives of many young people. But balancing college life and a full course load while keeping a chronic disease such as diabetes in check can make an exciting time much more challenging. Today, the Diabetes Scholars Foundation (Foundation) announced its 2015 college scholarship rec…

  • Olympian Kris Freeman and NASCAR Driver Ryan Reed to Share Their Courageous Stories with Children Who Have Type 1 Diabetes

    INDIANAPOLIS, June 8, 2015 /PRNewswire/ -- Olympic cross-country skier Kris Freeman and NASCAR XFINITY Series driver Ryan Reed will travel across the U.S. this summer to share their stories of perseverance and triumph as part of the Lilly Camp Care Package (LCCP) program. Kris and Ryan will speak to children at select diabetes summer camps about how type 1 diabetes did not stop them from chasing…

  • Lilly commits 780,000 additional vials of insulin to Life for a Child

    INDIANAPOLIS, June 4, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) has committed another 780,000 vials of insulin to the International Diabetes Federation's Life for a Child program. Life for a Child provides free, life-saving medicine to children living in impoverished communities who otherwise would not have access to the insulin they need. The International Diabetes Federation (IDF) i…

  • Lilly Sends Employees to Serve in Vulnerable Communities around the World

    INDIANAPOLIS, May 27, 2015 /PRNewswire/ -- Marcio Donatelli, a senior marketing associate with the animal health division of Eli Lilly and Company (NYSE: LLY), believes his volunteer work in a healthcare setting in Bangkok, Thailand, will be among the most humbling experiences of his life. "Caring for people in need with respect and dignity is the guiding star for me and my fellow volunteers," sh…